← Trials/Trial dossier/NCT07280221
WEgovy Real World Assessment of Weight Loss in Korea
WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea
Lead sponsor
Asset
Semaglutide
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
—
Enrollment
500
estimated
Study population
Obesity / overweight
Key I/E criterion
—
Primary endpoint
•Body weight, % change
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Study population text
Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.
Inclusion criteria
1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
3. Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
4. Male or female, aged ≥ 19 years at the time of signing the informed consent.
Exclusion criteria
1. Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
2. Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.
Endpoints (30)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
16 endpointsPercentage change in body weight
Time frame:From baseline (week 0) to 24 weeks
Body weight, % change
percent change from baseline, improvement
Absolute change in body weight
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Body weight, absolute change (kg)
change from baseline, improvement
Percentage change in body weight
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Body weight, % change
percent change from baseline, improvement
Achievement in body weight reduction more than or equal to (≥) 5%
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
≥5% weight-loss responders
threshold achievement, improvement
Achievement in body weight reduction ≥ 10%
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
≥10% weight-loss responders
threshold achievement, improvement
Achievement in body weight reduction ≥ 15%
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
≥15% weight-loss responders
threshold achievement, improvement
Achievement in body weight reduction ≥ 20%
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
≥20% weight-loss responders
threshold achievement, improvement
Change in body composition of Lean body mass
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Lean mass
change from baseline, improvement
Change in body composition of Total fat mass
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Total fat mass
change from baseline, improvement
Change in body composition of Lean body mass
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Lean mass
percent change from baseline, improvement
Change in body composition of Total fat mass
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Total fat mass
percent change from baseline, improvement
Change in Body mass index (BMI)
Time frame:From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks
BMI, change
change from baseline, improvement
Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
categorical status, improvement
Change in the proportion of patients by BMI Class II obesity (30 to 34.9 kg/m^2)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
categorical status, improvement
Change in the proportion of patients by BMI Class III obesity (≥35 kg/m^2)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
threshold achievement, improvement
Change in waist circumference
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Waist circumference, change
change from baseline, improvement
Glycemic / diabetes
3 endpointsChange in cardiometabolic parameters - Fasting plasma glucose (FPG)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Fasting glucose, change
change from baseline, improvement
LOINC 1558-6
Change in cardiometabolic parameters - Haemoglobin A1c (HbA1c)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
HbA1c, % change
percent change from baseline, improvement
LOINC 4548-4
Change in status of type two diabetes mellitus (T2DM)
Time frame:Baseline (week 0) to 52 weeks [or end of the study (EOS)]
categorical status, improvement
Cardiometabolic biomarkers
9 endpointsChange in cardiometabolic parameters - Systolic blood pressure (SBP)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Systolic BP, change
change from baseline, improvement
LOINC 8480-6
Change in cardiometabolic parameters - Diastolic blood pressure (DBP)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Diastolic BP, change
change from baseline, improvement
LOINC 8462-4
Change in cardiometabolic parameters - Lipids: total cholesterol (TCh)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Total cholesterol, change
change from baseline, improvement
LOINC 2093-3
Change in cardiometabolic parameters - Lipids: high-density lipoprotein cholesterol (HDL-C)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
HDL-C, change
change from baseline, improvement
LOINC 2085-9
Change in cardiometabolic parameters - Lipids: low-density lipoprotein cholesterol (LDL-C)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
LDL-C, change
change from baseline, improvement
LOINC 13457-7
Change in cardiometabolic parameters - Lipids: triglycerides (TG)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Triglycerides, change
change from baseline, improvement
LOINC 2571-8
Change in cardiometabolic parameters - Lipids: free fatty acid (FFA)
Time frame:From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Free fatty acids, change
change from baseline, improvement
Change in status of Hypertension
Time frame:Baseline (week 0) to 52 weeks (or EOS)
categorical status, improvement
Change in status of Dyslipidemia
Time frame:Baseline (week 0) to 52 weeks (or EOS)
categorical status, improvement
Safety / tolerability / PK
2 endpointsNumber of treatment-emergent adverse events (TEAEs)
Time frame:From baseline (week 0) to 52 weeks (or EOS)
Treatment-emergent AEs (any)
event count, event
Number of serious TEAEs
Time frame:From baseline (week 0) to 52 weeks (or EOS)
Serious AEs (any)
event count, event
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.